SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing

 (BUSINESS WIRE) -- Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request to continue its listing on the Nasdaq Stock Market, subject to stated conditions focused on timely completion of its financial audit and remediation of filing delinquencies.

Under the Panel’s decision, SINOVAC must, on or before May 11, 2026, demonstrate compliance with Nasdaq Listing Rule 5250(c)(1) and Listing Rule 5250(c)(2) by completing filings of its annual report for the year ended December 31, 2024 on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of year 2025 on Form 6-K.

As disclosed on January 4, 2026, the Company has engaged Zhonghua Certified Public Accountants LLP (“Zhonghua”) as its independent registered public accounting firm. SINOVAC is working diligently with Zhonghua to complete the required audit and to regain compliance with its filing obligations by May 11, 2026.

The Company remains committed to completing the requisite audit procedures and regulatory filings as expeditiously as practicable and to maintaining compliance with applicable U.S. Securities and Exchange Commission and Nasdaq requirements.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.

The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.

SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.

Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines, recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.

With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

For more information, please see the Company’s website at www.sinovac.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260122376718/en/

Permalink

https://www.aetoswire.com/en/news/2201202652564

Contacts

Investor and Media Contact

Sinovac Biotech Ltd.

Email: ir@sinovac.com

illumynt Appoints Chris Tejeda as Chief Revenue Officer

 BOSTON - Wednesday, 21. January 2026

(BUSINESS WIRE) -- illumynt today announced the promotion of Chris Tejeda to Chief Revenue Officer (CRO), reflecting the company’s continued growth and expanding global footprint.

In his new role, Tejeda will lead illumynt’s global revenue strategy, customer engagement, and strategic partnerships as demand accelerates for secure, technology-driven IT Asset Disposition (ITAD) solutions.

“Chris has been instrumental in aligning our commercial strategy with the evolving needs of hyperscale and enterprise customers,” said CEO Joerg Herbarth. “As AI accelerates infrastructure refresh cycles and raises the bar for security and compliance, his leadership will be critical to scaling illumynt with focus, transparency, and customer trust.”

Tejeda brings extensive experience in enterprise technology services and has played a key role in illumynt’s recent momentum, including significant revenue growth and the expansion of advanced capabilities across AI/GPU diagnostics, automation, and value recovery.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260121903784/en/

Permalink

https://www.aetoswire.com/en/news/2101202652490

Contacts

Alyson Kaye

617.407.6381

Sisvel Launches Wi-Fi Multimode Patent Pool

 LUXEMBOURG - Thursday, 22. January 2026 AETOSWire 

Ten patent owners establish licensing solution covering Wi-Fi 6 and Wi-Fi 7 standards

(BUSINESS WIRE) -- Sisvel has launched a groundbreaking Wi-Fi Multimode patent pool offering access to standard essential patents owned by 10 Wi-Fi 6 and Wi-Fi 7 technology leaders.

As the successor to Sisvel’s highly successful Wi-Fi 6 patent pool – which, over a three-year period, closed agreements with nearly 40 companies, including Acer, Netgear, Cisco and HP – the new programme offers an efficient way to access essential Wi-Fi rights for years to come.

The 10 founding patent owners in the Wi-Fi Multimode programme are Huawei, KPN, Mitsubishi Electric, Orange, Panasonic, Philips, Aegis 11 SA (a Sisvel affiliate), SK Telecom, Wilus and ZTE.

In addition, Sony Group Corporation has taken a licence under the Wi-Fi Multimode programme. This early agreement with a sophisticated and globally recognised Wi-Fi leader and implementer underlines the pool’s strong value proposition and the efforts made by Sisvel to engage with all parts of the market during pool formation.

Giorgia Varvelli has been named Wi-Fi Multimode programme manager; she previously held the same role for the Wi-Fi 6 patent pool, playing an instrumental role in its success.

“Today’s announcement is a milestone for Wi-Fi licensing,” says Sisvel President and CEO Mattia Fogliacco. “We have made it simple and straightforward to access essential rights across multiple Wi-Fi generations in a single transaction. This is the product of years of hard work by the Sisvel team and all our partners. We look forward to repaying the market’s trust in us to manage this critically important licensing programme.”

“It is exciting to be working with our returning Wi-Fi 6 licensors and the new patent owners that have come on board,” adds Varvelli. “With this programme, we continue to send a strong signal to the market: Wi-Fi innovation has value; and there is a transparent, efficient way to license essential rights. This will drive more R&D, more invention and more advanced technologies. Together with leading Wi-Fi implementers Sony, we are building a Wi-Fi licensing environment that powers innovation.”

Visit https://www.wifipatentpool.com for more information.

About Sisvel

Sisvel is driven by a belief in the importance of collaboration, ingenuity and efficiency to bridge the needs of patent owners and those who wish to access their technologies. In a complex and constantly evolving marketplace, our guiding principle is to create a level playing field with the development and implementation of flexible, accessible, commercialisation solutions.

Sisvel | We Power Innovation

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260122892826/en/

Permalink

https://www.aetoswire.com/en/news/2201202652562

Contacts

Media Contact

Giulia Dini

Head of Communications

Tel: +34 93 131 5570

giulia.dini@sisvel.com

IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio

ZUG, Switzerland - Thursday, 22. January 2026


    At IMCAS 2026, Galderma will present findings supporting Sculptra’s® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) Medical Device Regulation (MDR) certification, expanding its use to four body areas1-7
    Multiple studies will reinforce the safety and efficacy of Galderma’s hyaluronic acid (HA) treatments range, including post-marketing data on Restylane® Shaype™ in shaping the chin, Restylane Lyft™ in improving jawline definition, Restylane Skinboosters™ in smoothing fine lines and wrinkles in the décolletage and Restylane Volyme™ in correcting hollowing of the temples8-11
    New data on the innovative neuromodulator Relfydess™ (RelabotulinumtoxinA) will reinforce its rapid onset as early as Day 1 and sustained efficacy through six months for frown lines and crow’s feet12
    As a leader in injectable aesthetic innovation, Galderma will showcase its superior science and educational capabilities at the congress

 

(BUSINESS WIRE) -- Galderma (SIX: GALD) will present ten posters with the latest updates from across its broad aesthetic portfolio spanning regenerative biostimulation, HA and neuromodulator treatments at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The company will also showcase its leadership in community education through a number of events including two symposia, a live anatomy workshop, multiple masterclasses and meet-the-expert sessions, and a booth that will delve into the science behind its innovations.

“With ten posters spanning all key aesthetic treatment modalities and areas across the face and body, our data at IMCAS truly showcases the breadth and versatility of our injectable aesthetics portfolio and how we continue to drive innovation with our trusted products. In tandem with our first-class Galderma Aesthetic Injector Network (GAIN) educational activities, conducted in partnership with renowned experts, we are equipping practitioners with all the tools they need to take a personalized and holistic approach to treatment.”

BILL ANDRIOPOULOS, PH.D.

HEAD OF GLOBAL MEDICAL AFFAIRS

GALDERMA
    

 

Biostimulation: Sculptra’s innovative approach to regenerative aesthetics for the face and body backed by experts
In response to patients increasingly seeking harmony between facial and body aesthetics, Galderma recently announced the EU MDR certification of Sculptra, the first proven regenerative biostimulator, expanding its current clinical use to the body.3 At IMCAS, guidance developed by 13 international experts on Sculptra’s four MDR-approved indications – the gluteal area, posterior thighs, décolletage, and upper arms – will be presented.1 The experts concluded that Sculptra’s benefits can be complemented with Restylane Skinboosters in the décolletage for comprehensive body rejuvenation, and recommended injection volumes for Sculptra to be used in the posterior thighs, upper arms and gluteal area to improve aesthetic appearance, including skin firmness and reduced appearance of cellulite.1

Results from an expert review of data on Sculptra will also be presented, providing additional evidence of its regenerative properties.2 This includes fibroblast activation leading to stimulation of collagen, elastin and other proteins involved in extracellular matrix regeneration and adipogenesis (the formation of healthy fat cells).2 This clinically presents as long-term improvements such as increased volume, elasticity, and skin thickness.2

A final poster will examine the ease of Sculptra’s reconstitution process compared with two other poly-L-lactic acid biostimulators, finding that healthcare professionals had a strong preference for Sculptra’s reconstitution process and positively rated its speed of administration from preparation to injection.13

HA treatments: The Restylane range demonstrates its versatility in meeting diverse patient needs
Data from across Galderma’s portfolio of Restylane HA treatments will be presented supporting its versatile use on the face and décolletage, with a range of gel formulations to meet personalized needs from providing structural support to smoothing lines and wrinkles:

    The ARTIST post-marketing study found that Restylane Shaype, powered by new NASHA HD™ technology, is a safe and effective treatment for shaping the chin with natural-looking results, alone or in combination with Restylane Defyne™ and Restylane Lyft to provide lift, shape, and definition for diverse aesthetic needs.8 The poster also supports that Restylane Shaype has the highest G-prime (a measure of firmness) compared with other HA treatments produced with different manufacturing technologies, allowing for greater correction with lower injection volumes.8

    A study of Restylane Lyft for jawline definition showed it was effective and safe, and resulted in high subject satisfaction and aesthetic improvement through 12 months.9

    A study evaluating the effectiveness and safety of Restylane Skinboosters for correction of moderate-to-severe wrinkles in the décolletage found that it was well tolerated and highly efficacious with a significant improvement through Week 32 and high patient satisfaction.10

    A study of Restylane Volyme showed that it was safe and effective for correction of temple hollowing, with high and sustained results through Month 18 and high patient satisfaction.11

Neuromodulation: Supporting Relfydess’ next-generation performance
Results will be presented from an analysis of wrinkle morphology and dynamic skin strain in the RELAX and EXPRESSION trials investigating Relfydess – the first and only ready-to-use liquid neuromodulator created with PEARLTM Technology.12,14 Results reinforce its onset of action as early as Day 1 in patients with moderate-to-severe frown lines and crow’s feet, with sustained improvements for six months.12 Expert-led consensus recommendations will also be shared addressing important unmet needs in real-world clinical practice and providing clear guidance for the practical use of Relfydess, helping healthcare professionals select the optimal treatment protocol for their patients.15

Spearheading community education and awareness around unmet patient needs
Galderma will also present findings from a global survey of over 4,300 women across five continents linking menopause to several skin changes, including wrinkles, loss of firmness, dryness and dull skin, and the potential role of aesthetic treatments to address them.16,17 As part of its response to this, Galderma will host a symposium titled ‘Menopause in the Mirror: Challenges, Science and Aesthetic Solutions’ on Friday, January 30 at 10:30 AM – 12:30 PM CET in Grand Amphi - Level 1.

A second symposium, titled ‘Exploring Breakthroughs in Injectable Regeneration for the Face, Body, and Skin Health’ will delve into the growing demand for holistic regenerative aesthetic solutions and take place on Thursday January 29 at 1:30 – 2:30 PM CET in Room 251, Level 2.

More information about Galderma’s activities at IMCAS 2026 can be found here.

About Sculptra
Sculptra is the first proven regenerative biostimulator, with a unique poly-L-lactic acid (PLLA-SCA™) formulation, to provide progressive and sustained regenerative effect across all three skin layers.3,18-24 Sculptra reverses aging processes in the skin, including degradation of the extracellular matrix, which results in volume loss, laxity, and the appearance of wrinkles.3,18,19,25-27 Sculptra progressively rebuilds the skin’s structural foundation by encouraging the remodeling of components of the extracellular matrix, such as elastin and collagen, helping to gradually restore volume, firmness, radiance and skin quality, and the look of fullness to wrinkles and folds over time.3-7,18,19,28 Sculptra has been shown to provide visible improvements as early as one month after treatment, with results lasting up to two years.3,6,23,28,29

About the Restylane portfolio
Restylane HA treatments are designed differently to go beyond volumizing for natural-looking results.30-33 Our HA is minimally modified and our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose.34-37 Powered by NASHA®, NASHA HD, OBT™ and SB-NASHA™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.38-41 Trusted for almost three decades, our HA gels work in sync with your skin for 100% natural-looking results.30,42,43

About Relfydess (RelabotulinumtoxinA)
Pioneered by Galderma, Relfydess is the first and only ready-to-use liquid neuromodulator created with PEARL Technology that is designed to preserve molecule integrity.14 PEARL Technology is designed to deliver a highly active, innovative, complex-free molecule, with up to 39% of patients seeing effects from day one and up to 75% of patients maintaining improvements for six months.14,44,45 Relfydess is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.46,47 It was entirely created and manufactured by Galderma to expand its neuromodulator portfolio as part of the broadest Injectable Aesthetics portfolio on the market. Relfydess received a marketing authorization in several markets. RelabotulinumtoxinA is an investigational drug product in the U.S. Authorization conditions may vary internationally.

About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

    Haddad A, et al. International consensus: Sculptra®/Restylane® Skinboosters™ for non-facial rejuvenation. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

    Fabi SG, et al. Regenerative aesthetic effects of poly L-lactic acid treatment. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

    Sculptra®. EU Instructions for Use. 2025. Available online. Accessed January 2026.

    Galderma. Data on File. MA-57540.

    Nikolis A, et al. A Prospective, Multicenter Trial on the Efficacy and Safety of Poly-L-Lactic Acid for the Treatment of Contour Deformities of the Buttock Regions. J Drugs Dermatol. 2022;21(3):295–303. doi: 10.36849/JDD.5924.

    Beleznay K, et al. Safety and Effectiveness of Poly-L-lactic acid (PLLA-SCA) for the Improvement in Appearance of Cellulite – A Pilot Study. Poster presented at the IMCAS World Congress; February 1-3, 2024; Paris, France.

    Mazzuco R, et al. Clinical and Histological comparative outcomes after injections of Poly-L-Lactic Acid and Calcium Hydroxyapatite in arms – a split side study. J Cosmet Dermatol. 2022;21(12):6727–6733. doi: 10.1111/jocd.15356. Epub 2022 Sep 20.

    Nikolis A, et al. A new NASHA-HD, high G’ hyaluronic acid (HA) injectable evaluated for chin treatment in combination with lower face and mid-face HA filler treatment. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

    Rivers J, et al. Effectiveness and safety of Restylane® Lyft™ Lidocaine for jaw-line definition: A 12-month randomized controlled study. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

    Moradi A, et al. Effectiveness and safety of a hyaluronic acid skin quality injectable for the correction of wrinkles in the décolletage area. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

    Nestor M. Safety and effectiveness of an OBT™ hyaluronic acid filler for temple hollowing treatment: a randomized, controlled, clinical investigation. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

    Moradi A, et al. Objective image analysis of wrinkle morphology and dynamic skin strain in GLs and LCLs treated with relaBoNT-A in the RELAX and EXPRESSION trials. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

    Nikolis A, et al. Preferences and experiences across biostimulatory poly-L-lactic acid’s reconstitution processes and injection criteria (PREP study). Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

    Shridharani SM, et al. Efficacy and safety of RelabotulinumtoxinA, a new ready-to-use liquid formulation botulinum toxin: Results from the READY-1 double-blind, randomized, placebo-controlled phase 3 trial in glabellar lines. Aesthet Surg J. 2024;44(12):1330-1340. doi: 10.1093/asj/sjae131.

    Ascher B, et al. Consensus Recommendations on the Aesthetic Use of RelabotulinumtoxinA to Treat Upper Face Wrinkles. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

    Fabi SG, et al. The potential role of biostimulators/dermal fillers to address menopause-related skin conditions. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

    Galderma. Data on file. Menopause Patient Survey.

    Waibel J, et al. Bulk RNA-seq Analysis of Poly-L-Lactic Acid (PLLA-SCA) vs Calcium Hydroxyapatite (CaHA-R) Reveals a Novel, Adipocyte Mediated Regenerative Mechanism of Action Unique to PLLA. Poster presented at ASDS 2024 Annual Meeting; October 17-20, 2024; Orlando, Florida, United States.

    Waibel J, et al. Gene Analysis of Biostimulators: PLLA-SCA Triggers Regenerative Morphogenesis while CaHA-R Induces Inflammation upon Facial Injection. Poster presented at ASDS 2024 Annual Meeting; October 17-20, 2024; Orlando, Florida, United States.

    Huth S, et al. Molecular Insights into the effects of PLLA_SCA on Gene Expression and Collagen Synthesis in Human 3D Skin Models Containing Macrophages. J Drugs Dermatol. 2024;23(4):285–288. doi: 10.36849/JDD.7791.

    Galderma. Data on File. MA-46589.

    Vleggaar D, et al. Consensus recommendations on the use of injectable poly-L-lactic-acid for facial and nonfacial volumization. J Drugs Dermatol. 2014;13(4 Suppl):s44–s51.

    Widgegrow J, et al. A randomized, comparative study describing the gene signatures of poly-l-lactic acid (PLLA-SCA) and Calcium Hydroxyapatite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS World Congress; February 1-3, 2024. Paris, France.

    Duracinsky M, et al. Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients. BMC Infect Dis. 2014;14(474). doi: 10.1186/1471-2334-14-474.

    Zhang S and Duan E. Fighting against Skin Aging: The Way from Bench to Bedside. Cell Transplant. 2018;27(5):729–738. doi: 10.1177/0963689717725755.

    Shuster S, et al. The influence of age and sex on skin thickness, skin collagen and density. Br J Dermatol. 1975;93(6):639-43. doi: 10.1111/j.1365-2133.1975.tb05113.x.

    Zarbafian M, et al. The emerging field of regenerative aesthetics—where we are now. Dermatol Surg. 2022;48:101–108. doi: 10.1097/DSS.0000000000003239.

    Fabi S, et al. 24-month clinical trial data on effectiveness and safety after correction of cheek wrinkles using a biostimulatory poly-L-lactic acid injectable implant. Poster presented at IMCAS World Congress; January 26-28, 2023; Paris, France.

    Goldberg D, et al. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013;39(6):915–922. doi: 10.1111/dsu.12164.

    Di Gregorio C, et al. 25+ years of experience with the Restylane portfolio of injectable HA fillers for facial aesthetic treatment. E-poster presented at AMWC; March 27-29, 2024; Monaco.

    Nikolis A, et al. The role of clinical examination in midface volume correction using hyaluronic acid fillers: should patients be stratified by skin thickness? Aesthet Surg J Open Forum. 2020;2(1):1–12. doi: 10.1093/asjof/ojaa005.

    Talarico S, et al. High patient satisfaction of a HA filler producing enduring full-facial volume restoration: an 18- month open multicenter study. Dermatol Surg. 2015;41:1361–1369. doi: 10.1097/DSS.0000000000000549.

    Restylane. U.S. Instructions for use. Available online. Accessed January 2026.

    Edsman K, et al. Gel properties of hyaluronic acid dermal fillers. Dermatol Surg. 2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.

    Galderma. Data on file. MA-58650. Degree of modification of HA fillers.

    Seo K. Facial volumization with fillers. Springer. 2021;29–83. https://doi.org/10.1007/978-981-33-6212-3_2.

    Kablik J, et al. Comparative physical properties of hyaluronic acid dermal fillers. Dermatol Surg. 2009:35S(1):302–312. doi: 10.1111/j.1524-4725.2008.01046.x.

    Galderma Data on file. MA-56724. X-strain and G’ including Shaype.

    Nikolis A, et al. Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion. J Drugs Dermatol. 2024;23(4):255–261. doi: 10.36849/JDD.8145.

    Öhrlund Å et al. Differentiation of NASHA and OBT Hyaluronic Acid Gels According to Strength, Flexibility, and Associated Clinical Significance J Drugs Dermatol. 2024;23(1):1332–1336. doi: 10.36849/JDD.7648.

    Belmontesi M et al. Injectable Non-Animal Stabilized Hyaluronic Acid as a Skin Quality Booster: An Expert Panel Consensus J Drugs Dermatol. 2018;17(1):83–88.

    Solish N, et al. Dynamics of HA fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3):738-746. doi: 10.1111/jocd.12961.

    Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after HA filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-1606. doi: 10.1111/jocd.13205.

    Ablon G, et al. Treatment of lateral canthal lines with RelabotulinumtoxinA, an investigational liquid botulinum toxin: clinical efficacy and safety results from the READY-2 phase 3 trial. Toxicon. 2024;237(1):107353. doi: 10.1026/j.toxicon.2024.107353.

    Relfydess®. EU Summary of Product Characteristics.

    Sundberg AL and Stahl U. Relabotulinum toxin - a novel, high purity BoNT-A1 in liquid formulation. Presented at TOXINS; January 16-17, 2021; virtual meeting.

    Do M, et al. Purification process of a complex-free highly purified botulinum neurotoxin type A1 (BoNT-A1) - relabotulinumtoxinA. Presented at TOXINS; July 27-30, 2022; Louisiana, United States.

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260121547346/en/

Permalink
https://www.aetoswire.com/en/news/2201202652534

Contacts

For further information:

Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62

Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87

Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43

State Street and QNB Group Sign Strategic Agreement to Launch New Custody Servicing Model

 

Strengthening State Street’s Growth in Qatar and QNB’s International Presence

 

State Street Corporation (NYSE: STT) and QNB Group today at the World Economic Forum (WEF), announced a strategic alliance to introduce a new custody servicing model in Qatar. Under this co-operation agreement, State Street and QNB Group have agreed to collaborate, with service agreements to be finalized and executed at a later date.

In the presence of His Excellency Ali bin Ahmed Al Kuwari, Qatar’s Minister of Finance, the co‑operation agreement was signed during the WEF currently held in Davos, Switzerland, marking a significant milestone in State Street’s ongoing expansion within the Gulf Cooperation Council (GCC) and supporting QNB’s accelerating international growth.

This step reflects the strong market leadership of QNB Group, Qatar’s largest financial institution and a recognized leader in regional custody and asset‑servicing capabilities. The agreement will also strengthen QNB’s role as the country’s most trusted provider of local market access, regulatory expertise, and institutional‑grade safekeeping, as well as State Street’s market position in Qatar.

Bringing together State Street’s global scale and QNB’s deep local insight, this strategic alliance will enhance service delivery for clients and reinforce the two institutions’ combined presence in Qatar’s financial market.

“The GCC is one of the fastest-growing markets globally, and we are committed to deepening our presence through collaboration with leading local institutions”, said Ron O’Hanley, chairman and CEO at State Street. “This new servicing model creates significant synergies, enabling us to deliver enhanced solutions to clients across the region. QNB’s scale and network in Qatar are important to State Street as we invest further to support GCC clients in capturing opportunities driven by the region’s economic transformation.”

“This strategic alliance with State Street marks a pivotal moment for QNB Group and is fully aligned with our vision for sustained international expansion and market leadership,” said Abdulla Mubarak Al-Khalifa, Chief Executive Officer at QNB Group. “By leveraging State Street's world-class global custody and value-added services, we are significantly enhancing our operational capabilities and service offering. This collaboration is instrumental in further solidifying our position as a dominant financial institution both locally and across our expanding international footprint, allowing us to leverage State Street’s global expertise to expand our offerings and strengthen client relations, driving robust growth in key markets outside of Qatar. We are creating a superior servicing model that reflects our unwavering commitment to strategic partnerships, while maximizing stakeholder value on a global scale.”

With offices in Abu Dhabi, Dubai, Muscat and Riyadh, State Street has been servicing sovereign wealth funds, pension schemes, central banks, and asset managers in the Middle East for over three decades. State Street has a total of $12.92 trillion in asset under custody / administration and $841 billion of asset under management in EMEA.

QNB Group Custody received regulatory approval from the Qatar Financial Market Authority in 2012 to provide custody services both in Qatar and internationally, leveraging subsidiaries in Egypt and Turkey and an extensive global network of sub-custodians. With $65 billion in assets under custody, QNB Custody serves a diverse client base, including global custodians, financial institutions, asset managers, and government entities.

About State Street Corporation

State Street Corporation (NYSE: STT) is one of the world's leading providers of financial services to institutional investors including investment servicing, investment management and investment research and trading. With $53.8 trillion in assets under custody and/or administration and $5.7 trillion* in assets under management as of December 31, 2025, State Street operates globally in more than 100 geographic markets and employs approximately 52,000 worldwide. For more information, visit State Street's website at www.statestreet.com.

*Assets under management as of December 31, 2025 includes approximately $173 billion of assets with respect to SPDR® products for which State Street Global Advisors Funds Distributors, LLC (SSGA FD) acts solely as the marketing agent. SSGA FD and State Street Investment Management are affiliated.

About QNB Group

QNB Group is one of the leading financial institutions in the Middle East and Africa and is ranked as the most valuable banking brand in the MEA region. Present in over 28 countries across Asia, Europe, and Africa, it offers tailored products and services supported by innovation and backed by a team of over 31,000 professionals dedicated to driving banking excellence, worldwide.

© 2026 State Street Corporation

 

Permalink
https://aetoswire.com/en/news/qnbss22012026e

Contacts

For media inquiries, please contact: Khalil BouDargham KBouDargham@webershandwick.com

World Governments Summit 2026 to Include Largest International Participation Yet

 WGS 2026 Hosts High Level Investment Forum Latin America & Caribbean, and World Laureates Summit's Global First

 

The 2026 edition of the World Governments Summit (WGS) will host the largest ever international participation since its inception and convene several landmark forums, underlining its rising global stature and significance.

The roster of world-leading corporations and knowledge institutions at the global forum includes the International Monetary Fund (IMF), International Finance Corporation (IFC), a member of The World Bank, as well as more than 35 heads of state, government delegations, and 150+ governments.

WGS 2026 also hosts multiple world-class forums, notably the New Silk Road Forum, the high-level IFC-led Investment Forum - Latin America & the Caribbean, 10th International Cooperation Conference in collaboration with the Association of Caribbean States, and the Future of Economy Forum.

Also marking its global debut outside Shanghai, China is the World Laureates Summit (WLS), which brings together winners of the Nobel Prize, Turing Award, Fields Medal, Great Arab Minds, and major international scientific honorees. Taking place on 3-5 February,  the largest event of its kind to be hosted in collaboration with the World Laureates Association, will bring together laureates and world leaders to shape science-led solutions targeting pressing global challenges.

Notable attendees confirmed to attend include Michael Levitt (2013 Nobel in Chemistry), Kip Thorne (2017 Nobel in Physics), and John Hopcroft (1986 Turing Award).

The outcomes of the World Laureates Summit will be announced during WGS 2026.

The World Governments Summit 2026 will be held from 3-5 February under the theme ‘Shaping Future Governments’, with the largest international participation in the Summit’s history.

Comprising more than 320 sessions, the Summit will host over 100 international and regional organisations and 450+ global figures, including presidents, ministers, experts, thought leaders and decision-makers.

The World Governments Summit 2026 agenda features 24 specialised global forums dedicated to anticipating future trends across vital sectors.

 

Permalink

https://www.aetoswire.com/en/news/wgs2212026e

Contacts

Ahmed Yahya

ayahya@apcoworldwide.com

UAE Research Program for Rain Enhancement Science Announces Awardees of 6th Cycle Grants

 Abu Dhabi, United Arab Emirates - Wednesday, 21. January 2026 AETOSWire Print 

The UAE Research Program for Rain Enhancement Science (UAEREP), managed by the National Center of Meteorology (NCM), announced the awardees of its Sixth Cycle research grants. Each recipient will receive up to US$1.5 million over three years, with a maximum annual allocation of US$550,000.

The Sixth Cycle awardees are Dr. Dixon Michael, Principal Radar Meteorologist and Software Engineer at Echo Science Works, USA, for “Advancing Cloud Seeding Science with Dual-Polarization Radar Signatures and AI”; Prof. Linda Zou, Adjunct Professor at Victoria University, Australia, for “AI-assisted Development and Optimization of Glaciogenic Cloud Seeding Materials”; and Dr. Oliver Branch, Senior Scientist at the University of Hohenheim, Germany, for “Rainfall Enhancement through Modification of Land Cover and Land Form (RAINLAND).”

His Excellency Dr. Abdulla Al Mandous, President of the World Meteorological Organization and Director General of NCM, said: “Under the guidance of His Highness Sheikh Mansour bin Zayed Al Nahyan, Vice President, Deputy Prime Minister, and Chairman of the Presidential Court, UAEREP continues to strengthen its position as a global platform for scientific collaboration and applied innovation. NCM plays a central role in enabling this work through advanced infrastructure and operational expertise that translate research into real-world impact. This reflects the UAE’s approach of investing in practical and sustainable innovation.”

Alya Al Mazrouei, Director of UAEREP and Director of the Research and Weather Enhancement Department at NCM, said: “The awardees’ proposals demonstrate high standards of scientific innovation and practical application. Through UAEREP’s technical resources and global collaborations, these projects will deliver science-based solutions that contribute to water security and climate resilience.”

Dr. Dixon Michael’s project advances the evaluation of cloud seeding impacts beyond traditional reflectivity-based storm tracking. It will upgrade LROSE/TITAN to capture microphysical pathways and assess impacts using transparent, uncertainty-aware methods, while strengthening NCM’s capacity to sustain these systems.

Prof. Linda Zou’s project will develop advanced nanocomposite ice-nucleating materials and apply AI-driven analytics to optimize their performance using data from a Portable Ice Nucleation Experiment (PINE) cloud chamber, which will be deployed at NCM in the final phase of the project.

Dr. Oliver Branch’s RAINLAND project will apply a theory–observation–simulation approach to demonstrate how land-cover and land-topography modifications can trigger moist convection. The research aims to identify optimal land-form designs and locations to enhance rainfall in the UAE.

Permalink

https://www.aetoswire.com/en/news/2101202652492

Contacts

Salam Shehady

sshehady@apcoworldwide.com